Zestril Market Exclusivity

AstraZeneca PLC
26 November 2001




AstraZeneca Receives Six Months' Market Exclusivity for ZESTRIL(R) (lisinopril)


AstraZeneca announced today that the U.S. Food and Drug Administration (FDA)
granted six months' market exclusivity for the ACE inhibitor ZESTRIL(R)
(lisinopril) after the company complied with the FDA's written request for
information on the use of the medication in children.  The additional six
months' exclusivity extends AstraZeneca's US market protection for currently
marketed drug products containing lisinopril, which include ZESTRIL(R) and
ZESTORETIC(R) (lisinopril and hydrochlorthiazide) Tablets, through June 29,
2002.



Date: 26 November 2001


Media Enquiries:
Emily Denney,                    Tel: [phone]
Steve Brown,                     Tel: [phone]


Investor Relations:
Jorgen Winroth,                      Tel:  [phone]
Mina Blair Robinson,             Tel: [phone]



-Ends-